Drug Profile
SLS 010
Alternative Names: SLS-010Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals; Seelos Therapeutics
- Class Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Narcolepsy
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Narcolepsy in USA (PO)
- 11 Mar 2021 Preclinical development in narcolepsy is ongoing in USA (PO) (Seelos Therapeutics FORM 10-K, March 2021)
- 14 Mar 2019 SLS 010 is still in preclinical trials for narcolepsy in USA (Ligand Pharmaceuticals pipeline, March 2019)